Metronidazole Fresenius (Metronidazole)

Inside susceptible anaerobic organisms, Metronidazole is reduced to nitro radical anions. These reactive molecules damage DNA and inhibit nucleic acid synthesis, leading to bacterial or protozoal cell death while sparing aerobic host cells.

The dosage and duration of Metronidazole Fresenius are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Safety data for Metronidazole in pregnancy are limited, and the drug is classified as category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms and certain protozoa, offering a broad spectrum against Gram‑negative and Gram‑positive anaerobes. Alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations may be used, but Metronidazole often provides a more focused, cost‑effective option for infections where anaerobes predominate.

Metronidazole Fresenius should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use if the product appears discolored or particulate.

The product is supplied as a sterile injection for intravenous infusion. Administration is performed by qualified healthcare personnel, typically diluted in an appropriate compatible solution and infused over the period recommended by the prescriber, based on the infection being treated.

Serious adverse events, though rare, include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and hepatic dysfunction. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities, especially during prolonged therapy.

Metronidazole is contraindicated in patients with a known hypersensitivity to the drug or other nitroimidazoles. Caution is also advised for individuals with severe hepatic impairment, those taking disulfiram, and patients with a history of seizures or neuropathy until evaluated by a clinician.